Neurocrine launches PWS-VISTA study tracking VYKAT XR use in Prader-Willi syndrome
NBIX•Neurocrine launched PWS-VISTA, a real-world observational study tracking VYKAT XR use in Prader-Willi syndrome. A separate study will track caregiver-reported burden, while additional analyses will assess safety risks during treatment.
1. Studies track treatment
PWS-VISTA will follow VYKAT XR use in routine care and include baseline patient profiles. The separate BRAVE-PWS study will track caregiver-reported burden, and additional analyses will assess key safety risks during treatment. Findings will be presented in the future.
